A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update

R Eastell; D M Reid; J Compston; C Cooper; I Fogelman; R M Francis; D J Hosking; D W Purdie; S H Ralston; J Reeve; R G G Russell; J C Stevenson; D J Torgerson

A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update

R Eastell, D M Reid, J Compston, C Cooper, I Fogelman, R M Francis, D J Hosking, D W Purdie, S H Ralston, J Reeve, R G G Russell, J C Stevenson, D J Torgerson

Health Sciences

Research output: Contribution to journal › Literature review › peer-review

Abstract

In the UK, over 250 000 patients take continuous oral glucocorticoids (GCs), yet no more than 14% receive any therapy to prevent bone loss, a major complication of GC treatment. Bone loss is rapid, particularly in the first year, and fracture risk may double. This review, based wherever possible on clinical evidence, aims to provide easy-to-use guidance with wide applicability. A treatment algorithm is presented for adults receiving GC doses of 7.5 mg day(-1) or more for 6 months or more. General measures, e.g, alternative GCs and routes of administration, and therapeutic interventions, e.g, cyclical etidronate and hormone replacement, are recommended.

Original language	English
Pages (from-to)	271-292
Number of pages	22
Journal	Journal of general internal medicine
Volume	244
Issue number	4
Publication status	Published - Oct 1998

Keywords

adults
children
high-dose glucocorticoids
management and osteoporosis
CORTICOSTEROID-INDUCED OSTEOPOROSIS
BONE-MINERAL DENSITY
LOW-DOSE CORTICOSTEROIDS
INTESTINAL CALCIUM-ABSORPTION
CARDIAC TRANSPLANT RECIPIENTS
STEROID-INDUCED OSTEOPOROSIS
RHEUMATOID-ARTHRITIS
SERUM OSTEOCALCIN
DOUBLE-BLIND
VITAMIN-D

Cite this

@article{1c26482e557d46e3bba669c7389c5342,

title = "A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update",

abstract = "In the UK, over 250 000 patients take continuous oral glucocorticoids (GCs), yet no more than 14% receive any therapy to prevent bone loss, a major complication of GC treatment. Bone loss is rapid, particularly in the first year, and fracture risk may double. This review, based wherever possible on clinical evidence, aims to provide easy-to-use guidance with wide applicability. A treatment algorithm is presented for adults receiving GC doses of 7.5 mg day(-1) or more for 6 months or more. General measures, e.g, alternative GCs and routes of administration, and therapeutic interventions, e.g, cyclical etidronate and hormone replacement, are recommended.",

keywords = "adults, children, high-dose glucocorticoids, management and osteoporosis, CORTICOSTEROID-INDUCED OSTEOPOROSIS, BONE-MINERAL DENSITY, LOW-DOSE CORTICOSTEROIDS, INTESTINAL CALCIUM-ABSORPTION, CARDIAC TRANSPLANT RECIPIENTS, STEROID-INDUCED OSTEOPOROSIS, RHEUMATOID-ARTHRITIS, SERUM OSTEOCALCIN, DOUBLE-BLIND, VITAMIN-D",

author = "R Eastell and Reid, {D M} and J Compston and C Cooper and I Fogelman and Francis, {R M} and Hosking, {D J} and Purdie, {D W} and Ralston, {S H} and J Reeve and Russell, {R G G} and Stevenson, {J C} and Torgerson, {D J}",

year = "1998",

month = oct,

language = "English",

volume = "244",

pages = "271--292",

journal = "Journal of general internal medicine",

issn = "0884-8734",

publisher = "Springer",

number = "4",

}

TY - JOUR

T1 - A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update

AU - Eastell, R

AU - Reid, D M

AU - Compston, J

AU - Cooper, C

AU - Fogelman, I

AU - Francis, R M

AU - Hosking, D J

AU - Purdie, D W

AU - Ralston, S H

AU - Reeve, J

AU - Russell, R G G

AU - Stevenson, J C

AU - Torgerson, D J

PY - 1998/10

Y1 - 1998/10

N2 - In the UK, over 250 000 patients take continuous oral glucocorticoids (GCs), yet no more than 14% receive any therapy to prevent bone loss, a major complication of GC treatment. Bone loss is rapid, particularly in the first year, and fracture risk may double. This review, based wherever possible on clinical evidence, aims to provide easy-to-use guidance with wide applicability. A treatment algorithm is presented for adults receiving GC doses of 7.5 mg day(-1) or more for 6 months or more. General measures, e.g, alternative GCs and routes of administration, and therapeutic interventions, e.g, cyclical etidronate and hormone replacement, are recommended.

AB - In the UK, over 250 000 patients take continuous oral glucocorticoids (GCs), yet no more than 14% receive any therapy to prevent bone loss, a major complication of GC treatment. Bone loss is rapid, particularly in the first year, and fracture risk may double. This review, based wherever possible on clinical evidence, aims to provide easy-to-use guidance with wide applicability. A treatment algorithm is presented for adults receiving GC doses of 7.5 mg day(-1) or more for 6 months or more. General measures, e.g, alternative GCs and routes of administration, and therapeutic interventions, e.g, cyclical etidronate and hormone replacement, are recommended.

KW - adults

KW - children

KW - high-dose glucocorticoids

KW - management and osteoporosis

KW - CORTICOSTEROID-INDUCED OSTEOPOROSIS

KW - BONE-MINERAL DENSITY

KW - LOW-DOSE CORTICOSTEROIDS

KW - INTESTINAL CALCIUM-ABSORPTION

KW - CARDIAC TRANSPLANT RECIPIENTS

KW - STEROID-INDUCED OSTEOPOROSIS

KW - RHEUMATOID-ARTHRITIS

KW - SERUM OSTEOCALCIN

KW - DOUBLE-BLIND

KW - VITAMIN-D

M3 - Literature review

SN - 0884-8734

VL - 244

SP - 271

EP - 292

JO - Journal of general internal medicine

JF - Journal of general internal medicine

IS - 4

ER -